Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B

Hepatology Research

Volumn 44, Issue 1, 2014, Pages 1-8

  Tanaka, Eiji ^a   Matsumoto, Akihiro ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Discontinuation of treatment; Hepatitis B; Hepatitis B virus cccDNA; Hepatitis relapse; Nucleoside nucleotide analog

Indexed keywords

ANTIVIRUS AGENT; CCCDNA; NUCLEOSIDE ANALOG; NUCLEOSIDE NUCLEOTIDE ANALOG; UNCLASSIFIED DRUG; VIRUS DNA;

FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL; MEDICAL RESEARCH; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 84891832839     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12108     Document Type: Review

References (27)

1. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007; 132: 1574-1585.
2. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 7 (351): 1521-1531.
3. Matsumoto A, Tanaka E, Rokuhara A etal. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2795 patients. Hepatol Res 2005; 32: 173-184.
4. Lok AS, Zoulim F, Locarnini S etal. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46: 254-265.
5. Werle-Lapostolle B, Bowden S, Locarnini S etal. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
6. Matsumoto A, Tanaka E, Suzuki Y etal. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2012; 42: 139-149.
7. Tanaka, E, Matsumoto, A, Suzuki, Y etal. Guidelines for avoiding risks resulting from discontinuation of nucleos(t)ide analogues in patients with chronic hepatitis B (2012). Kanzo 2012; 53: 237-242.
8. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 11 (337): 1733-1745.
9. Mason WS, Halpern MS, England JM etal. Experimental transmission of duck hepatitis B virus. Virology 1983; 131: 375-384.
10. Summers J, Smith PM, Horwich AL. Hepadnavirus envelope proteins regulate covalently closed circular DNA amplification. J Virol 1990; 64: 2819-2824.
11. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 7 (47): 451-460.
12. Kimura T, Ohno N, Terada N etal. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 2005; 280: 21713-21719.
13. Rokuhara A, Matsumoto A, Tanaka E etal. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 2006; 41: 785-790.
14. Hatakeyama T, Noguchi C, Hiraga N etal. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 2007; 45: 1179-1186.
15. Chan HL, Wong VW, Tse AM etal. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468.
16. Moucari R, Lada O, Marcellin P. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-636.
17. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 2009; 81: 27-33.
18. Wong DK, Tanaka Y, Lai CL, Mizokami M, Fung J, Yuen MF. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 2007; 45: 3942-3947.
19. Kimura T, Rokuhara A, Sakamoto Y etal. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-445.
20. Tanaka E, Matsumoto A, Yoshizawa K, Maki N. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy. Intervirology 2008; 51 (Suppl 1): 3-6.
21. Hosaka T, Suzuki F, Kobayashi M etal. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-1470.
22. Kumada T, Toyoda H, Tada T etal. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 427-433.
23. Shinkai N, Tanaka Y, Orito E etal. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 2006; 36: 272-276.
24. Kumada H, Okanoue T, Onji M etal. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40: 1-7.
25. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
26. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
27. Lim SG, Wai CT, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597-599.